“`html
Apollomics (Nasdaq: APLM), a biopharmaceutical company focused on
oncology therapies, announced board changes on November 16-17, 2025.
Po-Jen Hsueh resigned from the board, with the company stating the
resignation was not due to any disagreement. The board appointed Dr.
Ya-Chi (Claudia) Huang to fill the vacancy and named her to the Audit
Committee and the Nominating and Corporate Governance Committee.
The seven-member Board now includes Hung-Wen (Howard) Chen (chair),
Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu,
Chen-Huan Jan, and Ya-Chi (Claudia) Huang, with five independent
directors. This composition reflects a commitment to independent
oversight, crucial for maintaining investor confidence and corporate
governance standards.
Dr. Huang’s background highlights biotechnology investment and R&D.
She is currently Assistant Vice President at Maxpro Ventures (joined
2024), director at AngenMed Therapeutics, and previously worked at
Diamond Biofund, where she participated in Diamond’s 2023 Taiwan Stock
Exchange IPO. She holds a Ph.D. in Microbiology from National Taiwan
University. Her experience in investment and pre-IPO companies could
prove valuable as Apollomics navigates the complex landscape of
biopharmaceutical development and potential future financing rounds.
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) — Apollomics
Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based
late-stage clinical biopharmaceutical company, today announced the
following update regarding changes to the Company’s board of directors
(“Board”) and composition of committees.
On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr.
Hsueh’s resignation was not related to any disagreement with the Company.
Pursuant to a meeting of the Board on November 16, 2025, Dr.
Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy
resulting from Mr. Hsueh’s resignation. Dr. Ya-Chi (Claudia) Huang will
also replace Mr. Po-Jen Hsueh as a member of the Company’s Audit
Committee and Nominating and Corporate Governance Committee. Following
these changes and the previously announced appointments of directors, the
Company’s Board is comprised of the following seven members: Hung-Wen
(Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu
Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Moses Chen,
Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang are
independent directors.
Biographical Information of the New Director
Dr. Ya-Chi (Claudia) Huang brings to the Board extensive experience in
biotechnology investment, corporate governance, and research and
development across Taiwan’s biopharmaceutical industry.
Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures,
where she leads domestic and international investment activities. Since
joining in 2024, she has successfully completed investments in multiple
companies and manages their post-investment operations. She also serves as
a director of AngenMed Therapeutics.
Previously, Dr. Huang served as Investment Manager at Diamond Biofund
(6901.TW), where she independently completed multiple investments and
oversaw post-investment management for all of Diamond’s portfolio
companies. She participated in Diamond Biofund’s IPO on the Taiwan Stock
Exchange in 2023. Earlier in her career, she was Deputy Manager in the
Research Department at Fubon Securities Investment Services, where she
evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong
Kong, and contributed to a significant increase in Fubon Securities’
investment banking profits.
Dr. Huang’s scientific background includes research positions at the
National Health Research Institutes, Development Center for Biotechnology,
and Academia Sinica. Her doctoral research on Epstein-Barr virus was
published in Blood and received the Distinguished Thesis Prize in the
12th TienTe Lee Biomedical Award.
Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University
College of Medicine and an M.S. in Biological Sciences from National Sun
Yat-sen University.
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical
company focused on the discovery and development of oncology therapies
with the potential to be combined with other treatment options to harness
the immune system and target specific molecular pathways to inhibit cancer.
Apollomics’ lead program is vebreltinib (APL-101), a potent, selective
c-Met inhibitor for the treatment of non-small cell lung cancer and other
advanced tumors with c-Met alterations, which is currently in a Phase 2
multicohort clinical trial in the United States and other countries.
The company’s pipeline, particularly vebreltinib (APL-101), a c-Met
inhibitor, warrants further investigation. The competitive landscape for
oncology therapies, including c-Met inhibitors, is crowded and rapidly
evolving. Investors should closely monitor Apollomics’ clinical trial data
and commercialization strategy in light of competing therapies from larger,
more established pharmaceutical companies. The appointment of Dr. Huang,
with her extensive network and experience in Taiwanese biotech investment,
could provide strategic advantages in accessing funding and partnerships in
the APAC region.
Cautionary Statement Regarding Forward-Looking
Statements
This press release includes statements that constitute “forward-looking
statements” within the meaning of the federal securities laws, including
Section 27A of the Securities Act of 1933, as amended (the “Securities
Act”), and Section 21E of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”). All statements, other than statements of present or
historical fact included in this press release, regarding Apollomics’
strategy, prospects, plans, objectives and anticipated outcomes from the
development and commercialization of vebreltinib are forward-looking
statements. When used in this press release, the words “could,” “should,”
“will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,”
“seek,” “project,” the negative of such terms and other similar
expressions are intended to identify forward-looking statements, although
not all forward-looking statements contain such identifying words. These
forward-looking statements are based on management’s current expectations
and assumptions about future events and are based on currently available
information as to the outcome and timing of future events. In addition,
Apollomics cautions you that the forward-looking statements contained in
this press release are subject to unknown risks, uncertainties and other
factors, including those risks and uncertainties discussed in the Annual
Report on Form 20-F for the year ended December 31, 2024, filed by
Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”)
under the heading “Risk Factors” and the other documents filed, or to be
filed, by Apollomics with the SEC. Additional information concerning
these and other factors that may impact the operations and projections
discussed herein can be found in the reports that Apollomics has filed
and will file from time to time with the SEC. Forward-looking statements
speak only as of the date made by Apollomics. Apollomics undertakes no
obligation to update publicly any of its forward-looking statements to
reflect actual results, new information or future events, changes in
assumptions or changes in other factors affecting forward-looking
statements, except to the extent required by applicable law.
FAQ
Who resigned from Apollomics’ board on November 16, 2025 (APLM)?
Mr. Po-Jen Hsueh resigned from the board on November 16, 2025; the company
said the resignation was not related to any disagreement.
Who was appointed to Apollomics’ board to replace Po-Jen Hsueh (APLM)?
Dr. Ya-Chi (Claudia) Huang was appointed to the board to fill the vacancy
and will join the Audit and Nominating and Corporate Governance Committees.
What is Dr. Ya-Chi (Claudia) Huang’s background and qualifications for Apollomics’ board (APLM)?
Dr. Huang is Assistant Vice President at Maxpro Ventures, director at
AngenMed Therapeutics, previously at Diamond Biofund (involved in its
2023 TWSE IPO), and holds a Ph.D. in Microbiology from National Taiwan
University.
How many directors are on Apollomics’ board after the November 2025 changes (APLM)?
The board has seven members after the change, with five classified as
independent directors.
Which Apollomics committees did the new director join after her appointment (APLM)?
Dr. Ya-Chi (Claudia) Huang replaced Po-Jen Hsueh as a member of the Audit
Committee and the Nominating and Corporate Governance Committee.
When was Dr. Ya-Chi (Claudia) Huang reported to have joined Maxpro Ventures and what has she done there (APLM)?
Dr. Huang joined Maxpro Ventures in 2024, where she leads domestic and
international investments and manages post-investment operations.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/13067.html
